We conducted a randomized , open-label , single-centre , non-inferiority trial comparing trimethoprim/sulfamethoxazole ( 160 mg/800 mg three times daily ) plus rifampicin ( 600 mg once a day ) versus linezolid ( 600 mg twice a day ) alone in adult patients with various types of MRSA infection .